TrialHaematologica2016
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Sylvain Thépot et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
28 papers cite it
this paperpooled ittrialcites it